Roche and Hansoh Pharmaceutical Group launched a second collaboration aimed at developing antibody-drug conjugates, expanding Roche’s ADC platform access and Hansoh’s pipeline monetization. The companies agreed to develop an unspecified number of ADCs “across multiple cancer types,” with two preclinical Hansoh ADC programs and additional programs tied to Roche-identified targets. The partnership follows Roche’s earlier license and investment in Hansoh’s colorectal-focused ADC HS-20110, which is already in Phase I/II studies in China and Phase I work in the U.S. and China for advanced solid tumors. Together, the structure underscores how large pharma is using repeat collaborations to accelerate target-to-ADC execution while sharing early discovery risk. For biotech decision-makers, the headline is scale—Roche-Hansoh’s new agreement is positioned as potentially exceeding $15 billion in value—and signal of sustained ADC demand for multi-target oncology strategies.